Sangamo Therapeutics (SGMOQ) Operating Expenses (2010 - 2025)

Sangamo Therapeutics' Operating Expenses history runs 16 years deep, the most recent figure standing at $52.4 million for Q4 2025.

• On a quarterly basis, Operating Expenses rose 56.32% year-over-year to $52.4 million in Q4 2025; TTM through Dec 2025 was $160.8 million, a 0.6% decrease from a year earlier, with the FY2025 full-year figure at $160.8 million, down 0.6% from the prior year.
• Operating Expenses climbed to $52.4 million in Q4 2025 per SGMOQ's latest filing, from $36.1 million in the prior quarter.
• Across five years, Operating Expenses topped out at $139.9 million in Q1 2023 and bottomed at $33.5 million in Q4 2024.
• The 5-year median for Operating Expenses is $70.2 million (2021), against an average of $69.0 million.
• Across the five-year window, Operating Expenses soared 90.39% in 2023 and sank 71.29% in 2024, its largest moves.
• Year by year, Operating Expenses stood at $67.9 million in 2021, then advanced by 21.71% to $82.6 million in 2022, then declined by 22.42% to $64.1 million in 2023, then plunged by 47.67% to $33.5 million in 2024, then soared by 56.32% to $52.4 million in 2025.
• Per Business Quant, the three latest SGMOQ Operating Expenses figures stand at $52.4 million (Q4 2025), $36.1 million (Q3 2025), and $36.2 million (Q2 2025).